TrialAdvances in therapy2026

Comparative Study Assessing Multiple Switches Between Biosimilar ABP 501 (adalimumab-atto) and Adalimumab Reference Product in Patients with Plaque Psoriasis.

Paul S Yamauchi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.